COMMON STOCK PURCHASE WARRANT NEXIEN BIOPHARMA, INC.Nexien Biopharma, Inc. • January 21st, 2022 • Pharmaceutical preparations • Florida
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of that certain secured convertible promissory note dated January 18, 2022, in the original principal amount of $170,454 issued by the Company (as defined below) to the Lender (as defined below) (the “Note”), Quick Capital, LLC, a Wyoming limited liability company (the “Lender” and including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the Exercise Period, to purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), 347,512 shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect. The number of Warrant Shares for which this Warrant may be exercised is subject to adjustment in accordance with the terms hereof. This Warrant is issued by the Company as of the Is
NOTE PURCHASE AGREEMENTNote Purchase Agreement • February 20th, 2024 • Nexien Biopharma, Inc. • Pharmaceutical preparations • Florida
THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 14, 2024, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein.
ContractNexien Biopharma, Inc. • February 11th, 2021 • Pharmaceutical preparations • Delaware
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO NEXIEN BIOPHARMA, INC.
Amended and Restated Share Exchange Agreement by and between Kinder Holding Corp. and Intiva BioPharma Inc. Dated as of October 13, 2017Share Exchange Agreement • October 16th, 2017 • Kinder Holding Corp. • Blank checks • Colorado
This AMENDED AND RESTATED SHARE EXCHANGE AGREEMENT, dated as of October 13, 2017 (this “Agreement”) is between Kinder Holding Corp., a Delaware corporation with offices located at 2275 Huntington Drive, Suite 851, San Marino, CA 91108, on the one hand (the “Company”) and Intiva BioPharma Inc., a Colorado corporation with offices located at 3773 Cherry Creek N. Drive, Suite 575, Denver CO 80209, on the other hand (“BioPharma”). The Company and BioPharma are sometimes referred to individually, as a “Party” and collectively, as the “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 15th, 2018 • Intiva BioPharma Inc. • Pharmaceutical preparations • Colorado
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 29th day of March, 2017, between KOTZKER CONSULTING LLC, a Delaware limited liability company having a business address of 20 Highview Ln, Yardley, PA 19067 (the “LICENSOR”) and INTIVA KOTZKER PHARMACEUTICALS INC., a Colorado corporation having a business address at 3773 Cherry Creek North Drive, Suite 575, Denver Colorado 80209 (the “LICENSEE”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 15th, 2018 • Intiva BioPharma Inc. • Pharmaceutical preparations • Colorado
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 28th day of February, 2018, between ACCU-BREAK PHARMACEUTICALS, INC., a Florida corporation having a business address of 6100 Hollywood Boulevard, Suite 207, Hollywood, FL 33024 (the “Licensor”) and INTIVA BIOPHARMA INC., a Delaware corporation having a business address at 4340 East Kentucky Avenue, Suite 206, Denver, CO 80246 (the “Licensee”).
Share Exchange Agreement by and between Kinder Holding Corp. and Intiva BioPharma Inc. Dated as of August 8, 2017Share Exchange Agreement • August 9th, 2017 • Kinder Holding Corp. • Blank checks • Colorado
This SHARE EXCHANGE AGREEMENT, dated as of August 8, 2017 (this "Agreement"), is by and between Kinder Holding Corp., a Delaware corporation with offices located at 2275 Huntington Drive, Suite 851, San Marino, CA 91108 (the "Company") and Intiva BioPharma Inc., a Colorado corporation with offices located at 3773 Cherry Creek N. Drive, Suite 575, Denver CO 80209 ("BioPharma"). The Company and BioPharma are sometimes referred to individually, as a "Party" and collectively, as the "Parties."
LIMITED LIABILITY COMPANY INTEREST PURCHASE AGREEMENT BY AND AMONG THE MEMBERS OF CRX BIO HOLDINGS LLC AND NEXIEN BIOPHARMA, INC. DATED OCTOBER 26, 2018Limited Liability Company Interest Purchase Agreement • October 30th, 2018 • Nexien Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Limited Liability Company Interest Purchase Agreement (“Agreement”) is made as of October 26, 2018, by and among Nexien BioPharma, Inc., a Delaware corporation (“Buyer”), and Joseph Aceto (“Aceto”), Frank Manganella (“Manganella”), Jeremy Reeh (“Reeh”), Alex Wasyl (“Wasyl”), Robert McKean, and Michael Fenn (collectively, “Sellers”).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 28th, 2018 • Nexien Biopharma, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT is made and entered into this 18th day of September, 2018 (the “Effective Date) between Accu-Break Pharmaceuticals, Inc. (“Licensor”) and Intiva BioPharma Inc. (“Licensee”) (the “Amendment”)
AMENDMENT AND SECOND EXTENSION OF NOTE PURCHASE AGREEMENTExtension of Note Purchase Agreement • May 15th, 2024 • Nexien Biopharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT AND SECOND EXTENSION OF NOTE PURCHASE AGREEMENT (this “Amendment”), dated as of February 29, 2024, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and Richard Greenberg (the “Buyer”).
AMENDMENT AND EXTENSION OF NOTE PURCHASE AGREEMENTAnd Extension of Note Purchase Agreement • September 28th, 2023 • Nexien Biopharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT AND EXTENSION OF NOTE PURCHASE AGREEMENT (this “Amendment”), dated as of May 8, 2023, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”).
